<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029599</url>
  </required_header>
  <id_info>
    <org_study_id>China.JLMXFYQ2008-01</org_study_id>
    <nct_id>NCT02029599</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maoxiang Group Jilin Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maoxiang Group Jilin Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of Fang yi qing Feng shi
      granules in subjects with Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fang yi qing feng shi granules is the chinese patent medicine, which contains 8 kinds of
      chinese medicine .

      Fang yi qing feng shi granules was approved by China Food and Drug Administration (CFDA) in
      2005, produced by means of modern technology by Maoxiang Group Jilin Pharmaceutical Co.,
      Ltd.The study is a multi-center, double -blind, placebo -controlled, randomized in Chinese
      subjects with Rheumatoid Arthritis to assess treatment effect and safety in the subjects
      treated with Fang yi qing feng shi granules versus subjects treated with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of Therapeutic effect with American College of Rheumatology standards (ACR)</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of Rheumatoid Arthritis (RA) associated symptoms and signs</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
    <description>The symptoms and signs include &quot;Tender joint count,swollen joint count,time of morning stiffness,mean grip strength, VAS score,Jint function&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The subjects of their comprehensive evaluation of disease activity(AIMS),The observer to the comprehensive evaluation of disease activity in the study(AIMS),The subjects of physical function evaluation(HAQ).</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of laboratory test indexes (ESR、RF、CRP)</measure>
    <time_frame>baseline,week12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese Medicine(TCM) characteristics evaluative index: Traditional Chinese medicine Syndrome Scale</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score of clinical symptoms and symptom integral</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the days and doses using of analgesic(Paracetamol Tablets)</measure>
    <time_frame>Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.
placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fang yi qing feng shi granule</intervention_name>
    <description>10g, Oral,Three each time, 3 times a day,for 3 months;</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>10g, Oral,Three each time, 3 times a day,for 3 months</description>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>The placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>7.5-15mg per week，All patients should be used</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>The placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen tablets</intervention_name>
    <description>Oral,0.5g, 1~2 times a day, when vas=10</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>The placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects have the diagnosis of Rheumatoid Arthritis in active state.

          2. Subjects have the Traditional Chinese Medicine (TCM) diagnosis ofArthralgic Syndrome
             with the sign of dampness obstructing connecting vessel。

          3. Subjects must stop the medicine at least three month，which is Diseases modifying
             anti-rheumatic drugs(including glucocorticoids).

          4. Male or female subjects, between the ages of 18 and 65 years old.

          5. Joint function grading and ray classification are both in Ⅰ～Ⅲ.

          6. Subjects agree to participate in this study and sign the informed consent form.

        Exclusion Criteria:

          1. Subjects with systemic lupus erythematosus,sicca syndrome, or severe osteoarthropathy
             will be excluded.

          2. Subjects with severe rheumatic arthritis are loss of ability

          3. Allergic to test drugs(basic treatment or drug combination),Allergic
             constitution(Allergic to two or more drugs).

          4. Female subject who was pregnant or breast-feeding or considering becoming pregnant.

          5. Subjects with sever diseases in Cardiovascular, brain, lung, liver, kidney and
             hematopoietic system.

          6. The Liver function (ALT,AST) and kidney function（BUN,Cr）is higher than normal.

          7. The Blood Routine (leukocyte count,platelet count)is lower than normal.

          8. Subject considered by the investigator, for any reason, to be an unsuitable candidate
             for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wei liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hubei provincial hospital of tcm</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Liaoning University of Traditional Chinese Medicine</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LONGHUA Hospital Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Teaching hospital of Tianjin University of Traditional Chinese Medicine</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second affiliated hospital of Tianjin university of tcm</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

